Prepubertal bipolar disorder: Proper diagnosis should lead to better treatment response

2005 ◽  
Vol 7 (2) ◽  
pp. 104-111 ◽  
Author(s):  
Edith M. Jolin ◽  
Elizabeth B. Weller ◽  
Ronald A. Weller
Keyword(s):  
Bipolar Disorder ◽  
Treatment Response ◽  
Proper Diagnosis

Prepubertal bipolar disorder: Proper diagnosis should lead to better treatment response

2005 ◽  
Vol 3 (3) ◽  
pp. 103-110
Author(s):  
Edith M. Jolin ◽  
Elizabeth B. Weller ◽  
Ronald A. Weller
Keyword(s):  
Bipolar Disorder ◽  
Treatment Response ◽  
Proper Diagnosis

Differential clinical characteristics, medication usage, and treatment response of bipolar disorder in the US versus The Netherlands and Germany

2011 ◽  
Vol 26 (2) ◽  
pp. 96-106 ◽  
Author(s):  
Robert M. Post ◽  
Gabriele S. Leverich ◽  
Lori L. Altshuler ◽  
Mark A. Frye ◽  
Trisha Suppes ◽  
...  
Keyword(s):  
Bipolar Disorder ◽  
The Netherlands ◽  
Treatment Response ◽  
Clinical Characteristics ◽  
Medication Usage ◽  
The Us

scholarly journals Prophylaxis Latency and Outcome in Bipolar Disorders

2003 ◽  
Vol 48 (7) ◽  
pp. 449-457 ◽  
Author(s):  
Christopher Baethge ◽  
Leonardo Tondo ◽  
Irene M Bratti ◽  
Tom Bschor ◽  
Michael Bauer ◽  
...  
Keyword(s):  
Bipolar Disorder ◽  
Treatment Response ◽  
Prophylactic Treatment ◽  
Bipolar Disorders ◽  
Mood Stabilizer ◽  
Adult Patients ◽  
Apparent Reduction

Objective: To analyze new and reviewed findings to evaluate relations between treatment response and latency from onset of bipolar disorder (BD) to the start of mood-stabilizer prophylaxis. Method: We analyzed our own new data and added findings from research reports identified by computerized searching. Results: We found 11 relevant studies, involving 1485 adult patients diagnosed primarily with BD. Reported latency to prophylaxis averaged 9.6 years (SD 1.3), and follow-up in treatment averaged 5.4 years (SD 3.1). Greater illness intensity and shorter treatment latency were closely associated, resulting in a greater apparent reduction in morbidity with earlier treatment. However, this finding was not sustained after correction for pretreatment morbidity, and treatment latency did not predict morbidity during treatment. Therefore, assessments based on improvement with treatment, or without correction for pretreatment morbidity, can be misleading. Conclusions: Available evidence does not support the proposal that delayed prophylaxis may limit response to prophylactic treatment in BD and related disorders.

scholarly journals Polygenic scores for major depressive disorder and depressive symptoms predict response to lithium in patients with bipolar disorder

2018 ◽  
Author(s):  
Azmeraw T. Amare ◽  
Klaus Oliver Schubert ◽  
Liping Hou ◽  
Scott R. Clark ◽  
Sergi Papiol ◽  
...  
Keyword(s):  
Bipolar Disorder ◽  
Major Depressive Disorder ◽  
Depressive Symptoms ◽  
Depressive Disorder ◽  
Treatment Response ◽  
Lithium Treatment ◽  
Mapk Signaling ◽  
Genome Wide Association Studies ◽  
Major Depressive ◽  
Polygenic Scores

AbstractBackgroundLithium is a first-line medication for bipolar disorder (BD), but only ~30% of patients respond optimally to the drug. Since genetic factors are known to mediate lithium treatment response, we hypothesized whether polygenic susceptibility to the spectrum of depression traits is associated with treatment outcomes in patients with BD. In addition, we explored the potential molecular underpinnings of this relationship.MethodsWeighted polygenic scores (PGSs) were computed for major depressive disorder (MDD) and depressive symptoms (DS) in BD patients from the Consortium on Lithium Genetics (ConLi+Gen; n=2,586) who received lithium treatment. Lithium treatment outcome was assessed using the ALDA scale. Summary statistics from genome-wide association studies (GWAS) in MDD (130,664 cases and 330,470 controls) and DS (n=161,460) were used for PGS weighting. Associations between PGSs of depression traits and lithium treatment response were assessed by binary logistic regression. We also performed a cross-trait meta-GWAS, followed by Ingenuity® Pathway Analysis.OutcomesBD patients with a low polygenic load for depressive traits were more likely to respond well to lithium, compared to patients with high polygenic load (MDD: OR =1.64 [95%CI: 1.26-2.15], lowest vs highest PGS quartiles; DS: OR=1.53 [95%CI: 1.18-2.00]). Associations were significant for type 1, but not type 2 BD. Cross-trait GWAS and functional characterization implicated voltage-gated potassium channels, insulin-related pathways, mitogen-activated protein-kinase (MAPK) signaling, and miRNA expression.InterpretationGenetic loading to depression traits in BD patients lower their odds of responding optimally to lithium. Our findings support the emerging concept of a lithium-responsive biotype in BD.FundingSee attached details

Cognitive function, treatment response to lithium, and social functioning in Japanese patients with bipolar disorder

2017 ◽  
Vol 19 (7) ◽  
pp. 552-562 ◽  
Author(s):  
Satoshi Saito ◽  
Kumiko Fujii ◽  
Yuji Ozeki ◽  
Kenichi Ohmori ◽  
Gyo Honda ◽  
...  
Keyword(s):  
Bipolar Disorder ◽  
Cognitive Function ◽  
Treatment Response ◽  
Social Functioning ◽  
Japanese Patients

scholarly journals Intrinsic functional neurocircuitry associated with treatment response to transdiagnostic CBT in bipolar disorder with anxiety

2018 ◽  
Vol 238 ◽  
pp. 383-391 ◽  
Author(s):  
Kristen K. Ellard ◽  
Aishwarya G. Gosai ◽  
Emily E. Bernstein ◽  
Navneet Kaur ◽  
Lousia G. Sylvia ◽  
...  
Keyword(s):  
Bipolar Disorder ◽  
Treatment Response

Correlation between white blood cell count and mood-stabilising treatment response in two bipolar disorder trials

2019 ◽  
Vol 31 (04) ◽  
pp. 230-234
Author(s):  
Ole Köhler-Forsberg ◽  
Louisa G. Sylvia ◽  
Charles L. Bowden ◽  
Joseph R. Calabrese ◽  
Michael E. Thase ◽  
...  
Keyword(s):  
Bipolar Disorder ◽  
Immune System ◽  
Blood Cell ◽  
Treatment Response ◽  
White Blood Cell ◽  
Standard Dose ◽  
Specific Treatment ◽  
Disorder Treatment ◽  
Pre Treatment ◽  
Personalised Treatment

AbstractBackground:Immune system markers may predict affective disorder treatment response, but whether an overall immune system marker predicts bipolar disorder treatment effect is unclear.Methods:Bipolar CHOICE (N = 482) and LiTMUS (N = 283) were similar comparative effectiveness trials treating patients with bipolar disorder for 24 weeks with four different treatment arms (standard-dose lithium, quetiapine, moderate-dose lithium plus optimised personalised treatment (OPT) and OPT without lithium). We performed secondary mixed effects linear regression analyses adjusted for age, gender, smoking and body mass index to investigate relationships between pre-treatment white blood cell (WBC) levels and clinical global impression scale (CGI) response.Results:Compared to participants with WBC counts of 4.5–10 × 109/l, participants with WBC < 4.5 or WBC ≥ 10 showed similar improvement within each specific treatment arm and in gender-stratified analyses.Conclusions:An overall immune system marker did not predict differential treatment response to four different treatment approaches for bipolar disorder all lasting 24 weeks.

14.4 Neuroimaging to Predict Treatment Response in Youth With and at Risk for Bipolar Disorder

2017 ◽  
Vol 56 (10) ◽  
pp. S324
Author(s):  
Kiki Chang ◽  
Amy Garrett ◽  
Meghan E. Howe ◽  
Manpreet K. Singh
Keyword(s):  
At Risk ◽  
Bipolar Disorder ◽  
Treatment Response ◽  
Predict Treatment Response
Sign in / Sign up

Export Citation Format

Share Document